Supercharge Your Innovation With Domain-Expert AI Agents!

Compositions and methods for the treatment of hepatitis c

A technology of hepatitis C virus and composition, applied in the direction of biochemical equipment and methods, chemical equipment and methods, drug combinations, etc.

Inactive Publication Date: 2011-08-10
ADURO BIOTECH
View PDF18 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these regimens established superior efficacy and tolerability over the current standard of care in the chronic HCV setting

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for the treatment of hepatitis c
  • Compositions and methods for the treatment of hepatitis c
  • Compositions and methods for the treatment of hepatitis c

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0412] Example 1. Development of ANZ 100

[0413] The L. monocytogenes ANZ 100 vaccine platform strain was derived from L. monocytogenes strain DP L4056, a prophage-free derivative of L. monocytogenes strain 10403S, itself a streptomycin-resistant variant of wild-type L. monocytogenes strain 10403. Strain Lm 10403 was first isolated from human skin lesions (Edman 1968) and streptomycin-resistant strain 10403S was first described by Bishop and Hinrichs (Bishop 1987). Streptomycin resistance in 10403S was mapped to a single mutation at codon 56 of the ribosomal protein gene rpsL, in which a T to C nucleic acid substitution resulted in the insertion of an R (Lys) at position 56 instead The K(t(Arg) amino acid, the method used to isolate strain DP L4056 from Lm 10403S was previously described in detail (Lauer 2002).

[0414] Removal of actA and inlB pathogenic genes is accomplished by homologous recombination. The deletion of each gene requires three steps: (1) construction of a...

Embodiment 2

[0416] Example 2. Evaluation of HCV antigens

[0417] The Kyte-Doolittle Hydrophilic Chart is a widely used scale for depicting the hydrophobic properties of proteins. Hydrophobicity was calculated from the solvation enthalpy of individual amino acid residues and summed over a sliding window of 5 to 7 amino acids. A domain property with a value above 0 is hydrophobicity. Initial Kyte-Doolittle evaluations of HCV core, NS3 and NS5b antigens were used to identify regions less than or equal to peak hydrophobicity values ​​derived from ActA-N100. Values ​​greater than this may represent polypeptide sequences that do not express well in Listeria. The results are shown in Figure 7 .

[0418] Figure 8 Recombinant expression of Listeria antigens by various ActA-N100HCV antigen fusions is shown, as measured by Western blot. Individual HCV sequences (core sequences 1-190, 1-180, and 1-177; NS3 sequences 1-631, 1-484, 22-631, 22-484, 22-280, 172-484, 172-631, and 416 -631; and N...

Embodiment 3

[0425] Example 3. Development of ANZ 521

[0426] L. monocytogenes strain ANZ 521 is a Listeria vaccine strain based on the ANZ 100 vaccine platform. Figures showing the source and derivation of ANZ 521 are provided in figure 1 .

[0427] To develop ANZ 521, the antigen expression cassette ( figure 2 A) Constructed under the control of a bacterial promoter (L. monocytogenes ActA promoter) encoding portions of the HCV gene products NS5b and NS3. The expression cassette is stably integrated into the L. monocytogenes genome ( figure 2 B). The L. monocytogenes actA promoter was chosen because it is highly inducible in host cells. The HCV antigen comprising the NS5b and NS3 sequences is expressed as a single polypeptide fused to the amino-terminal 100 amino acids of the ActA protein ("ActA-N100"), which maximizes the expression and secretion of the HCV NS5B-NS3 fusion protein from bacteria that In the context of APCs infected in the inoculated host.

[0428] The expressed ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides compositions and methods for delivery of one or more hepatitis C virus (HCV) antigens using a bacterium recombinantly encoding and expressing such antigens. In certain embodiments, the bacterial platform comprises the use of attenuated and killed but metabolically active forms of Listeria monocytogenes.

Description

[0001] Statement Regarding Federally Funded Research or Development [0002] This invention was made in part with United States Government support under Grant No. 1 U01 AI070834-01 awarded by the National Institutes of Health. The government may have certain rights in this invention. technical field [0003] The present invention generally relates to the treatment of subjects having or at risk of having hepatitis C infection. More specifically, the present invention relates to compositions and methods for delivering one or more hepatitis C virus (HCV) antigens using bacteria recombinantly encoding and expressing such antigens. Background technique [0004] The following discussion of the background of the invention is merely provided to assist the reader in understanding the invention and is not intended to describe or constitute prior art to the invention. [0005] Hepatitis C is the leading cause of morbidity and mortality worldwide. An estimated 170 million people worl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/29A61K39/00
CPCA61K2039/57C12N2830/55A61K2039/523A61K2039/5256C07K2319/00A61K2039/5254A61K39/29C07K14/005C12N2770/24222C12N2770/24234A61K39/12A61P1/16A61P31/04A61P31/14A61P37/04A61K38/16
Inventor P·M·劳尔T·W·小杜本斯盖
Owner ADURO BIOTECH
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com